Mendus AB: Mendus to participate in upcoming conferences in September

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell-based immunotherapies, today announced its participation in the following upcoming conferences:

LSX Nordic Congress 2022

Copenhagen, Denmark, September 6-7, 2022

Mendus CEO Erik Manting will present on September 6th, 2022, at 3:30 pm CET as part of the “Investable-Showcase” track.

https://www.lsxleaders.com/lsx-nordic-congress

 

Pareto Securities’ 13th Annual Healthcare Conference

Stockholm, Sweden, September 7-8, 2022

Mendus CEO Erik Manting will present on September 8th, 2022, at 2:30 pm CET.

https://paretosec.com/updates/events-and-conferences/

 

Sachs 22nd Annual Biotech in Europe Forum

Basel, Switzerland, September 21-22, 2022

Mendus CEO Erik Manting will participate in the “Immuno-Oncology BD & Partnering” panel discussion on Wednesday, 21st of September.

https://www.sachsforum.com/22bef-about.html

 

HollandBIO and Oncode Institute’s Next Frontiers in Cancer Vaccines Event

Amsterdam, The Netherlands, September 28, 2022

Mendus CEO Erik Manting will present at 3:10 pm CET.

https://www.hollandbio.nl/event/biotech-wednesday-next-frontiers-in-cancer-vaccines-2/

 

 

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: ir@mendus.com

 

INVESTOR RELATIONS

Julie Seidel

Stern Investor Relations

Telephone: +1 212-362-1200

E-mail: julie.seidel@sternir.com

 

MEDIA RELATIONS

Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu

 

ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/

 

Attachment